Drugs / Lormetazepam
Lormetazepam
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 31 trial | ||||||
| Phase 3 | NCT02374567 | Jan 2015 → Jun 2017 | anxiety disorder, dementia, depressive disorder, schizophrenia +1 | Hannover Medical School | Terminated | No outcome recorded |
| Phase 41 trial | ||||||
| Phase 4 | NCT02022592 | Jul 2014 → Dec 2019 | — | Claudia Spies | Completed | No outcome recorded |
| Comparator or background therapy2 trials | ||||||
| Phase 3 | NCT00788515 Comparator | Nov 2008 → Jan 2009 | sleep disorder, initiating and maintaining sleep | Sanofi | Terminated | No outcome recorded |
| Phase 3 | NCT00679900 Comparator | Apr 2008 → Mar 2009 | sleep disorder, initiating and maintaining sleep | Sanofi | Completed | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Lormetazepam | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02374567 ↗ |
| Known as | Chlorotemazepam | ChEMBL registry synonym — accepted as the source's own label CHEMBL22097 ↗ |
| Known as | Loramet | ChEMBL registry synonym — accepted as the source's own label CHEMBL22097 ↗ |
| Known as | Methyllorazepam | ChEMBL registry synonym — accepted as the source's own label CHEMBL22097 ↗ |
| Known as | WY-4082 | ChEMBL registry synonym — accepted as the source's own label CHEMBL22097 ↗ |
| Modality | Small molecule | — CHEMBL22097 ↗ |
| Route | Intravenous | “newly available intravenous drug Lormetazepam” NCT02022592 ↗ |